We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
BioClonetics Immunotherapeutics is a biotechnology company with a proprietary meth...
BioClonetics Immunotherapeutics is a biotechnol...
SelenBio, Inc is a biotechnology company specializing in the prevention of bacteri...
SelenBio, Inc is a biotechnology company specia...
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
Akers Biosciences, Inc. (aka Akers Bio) was founded in 1989, with the objective of...
Akers Biosciences, Inc. (aka Akers Bio) was fou...
We are a global medical technology company that develops, manufactures, and market...
We are a global medical technology company that...
Join the National Investor Network and get the latest information with your interests in mind.